Showing results (21-30 of 114) with videos related to
Sort By:
Pageof 12
Journal of Personalized Medicine|January 21, 2022
Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with CancerMichael J Duffy, John CrownClinical Chemistry|May 10, 2013
Companion biomarkers: paving the pathway to personalized treatment for cancerMichael J Duffy, John CrownCritical Reviews in Clinical Laboratory Sciences|November 8, 2023
Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?Michael J Duffy, John CrownInternational Journal of Cancer|July 9, 2020
Drugging "undruggable" genes for cancer treatment: Are we making progress?Michael J Duffy, John CrownClinical Chemistry|August 13, 2022
Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein BiomarkersMichael J Duffy, John CrownCancer Treatment Reviews|August 6, 2010
Use of molecular markers for predicting therapy response in cancer patientsMichael J Duffy, Norma O'Donovan, John CrownSeminars in Cancer Biology|September 9, 2017
Prognostic and predictive biomarkers in breast cancer: Past, present and futureAndrea Nicolini, Paola Ferrari, Michael J DuffyMedical Oncology (Northwood, London, England)|July 14, 2022
Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cellsShane O'Grady, John Crown, Michael J DuffyInvestigational New Drugs|January 28, 2025
Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630Minhong Tang, John Crown, Michael J DuffyTargeted Oncology|August 15, 2025
MYC as a Target for Cancer Treatment: from Undruggable to Druggable?Michael J Duffy, Minhong Tang, John CrownPageof 12